AbbVie's Botox Meets Key Goals in 2nd Platysma Prominence Study
September 18 2023 - 9:59AM
Dow Jones News
By Colin Kellaher
A second late-stage study of AbbVie's antiwrinkle treatment
Botox has met its key goals in platysma prominence, a part of the
aging process that disrupts the neck, jawline and lower face.
AbbVie's Allergan unit on Monday said the Phase 3 study of Botox
in the treatment of moderate-to-severe platysma prominence met all
primary and secondary endpoints, with study results consistent with
findings from a prior Phase 3 study.
Allergan said it will include the study data as part of a U.S.
Food and Drug Administration regulatory submission it expects to
file near the end of the year, adding that an FDA green light would
make Botox the first and only neurotoxin for platysma prominence,
which results from contraction of a superficial, flat muscle in the
lower face and neck.
Botox, which the FDA first approved in 1989 for a pair of rare
eye muscle disorders, is currently FDA-approved for a raft of
cosmetic and therapeutic indications. AbbVie posted combined Botox
cosmetic and therapeutic revenue of more than $2.8 billion for the
first half of 2023.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 18, 2023 09:44 ET (13:44 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From May 2024 to Jun 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2023 to Jun 2024